OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Equity Capital Raises
Equity Transaction Chart
Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.
Week ended 10/21/2022
Week ended 10/21/2022
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Equity Commentary
Week ended 10/21/2022
The Week’s Largest Closed Equity Transaction:
- On October 19, 2022, Empyrean Neuroscience (Privat) closed a Series A funding round for $22M.
- Empyrean is attempting to use genetic engineering techniques to modify the genomes of fungi and plants to change the amount and kind of neuroactive molecules they produce, intending to develop treatments for CNS disorders.
- The company’s initial focus is on Major Depressive Disorder, but it plans extensions to PTSD, substance abuse, and chronic pain.
- Proceeds will fund the development of therapeutics.
Public Company Raises:
- Four of the five companies that raised capital this week were public. All four trade in Canada (two on the CSE, one on TSX, and one on NEO) and in the U.S. (one on OTCQX, one on OTCQB, and two on OTC.)
Equity vs. Debt Cap Raises:
- Equity accounted for 99.1% of this week’s capital raises.
Week ended 10/21/2022
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Weekly Valuation Tracker
Viridian highlights a specific industry sector and provides a deep dive into valuation metrics and comparable company valuations for public companies operating in that sector. The Weekly Valuation Tracker provides proprietary, actionable valuation data.
- Week ended 10/21/2022
This week’s valuation tracker focuses on the 7 U.S. MSOs with market cap over $500M in the Viridian Value Tracker database in gauge the valuation impact of the 2nd earnings that have been released so far, Green Thumb (GTII: CSE), Curaleaf (CURA: CSE), and Trulieve.
- Week ended 10/21/2022
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.